Philip Stroisch

As Chief of Staff at CureVac, Philip Stroisch plays a pivotal role in shaping the company's strategic direction and operational excellence, particularly in advancing innovative RNA-based therapeutics. His current responsibilities involve close collaboration with CureVac’s CEO and leadership team to identify, prioritize, and execute key initiatives that accelerate the development of groundbreaking medicines in infectious diseases, oncology, and molecular therapy. Leveraging his expertise in business strategy, project management, and corporate development, Philip ensures that cross-functional teams are aligned and that strategic projects are delivered efficiently, fostering a culture of innovation and agility within the organization.

Philip’s work is deeply rooted in translating cutting-edge science and technology into tangible patient benefits. His hands-on experience on both sides of the Atlantic, combined with a design thinking approach and analytical problem-solving skills, enables him to navigate complex scientific and commercial landscapes. This holistic perspective is crucial as CureVac explores new modalities and expands its pipeline, positioning the company at the forefront of RNA therapeutics. Additionally, Philip contributes to organizational development initiatives, helping to build a resilient and adaptive corporate structure that supports rapid innovation and sustainable growth.

Through his leadership, CureVac is well-positioned to advance its mission of transforming healthcare with RNA technology. His strategic insights and operational expertise are instrumental in driving forward the company’s vision of delivering impactful, next-generation medicines that address unmet medical needs worldwide.